These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 19222850)

  • 1. A-002 (Varespladib), a phospholipase A2 inhibitor, reduces atherosclerosis in guinea pigs.
    Leite JO; Vaishnav U; Puglisi M; Fraser H; Trias J; Fernandez ML
    BMC Cardiovasc Disord; 2009 Feb; 9():7. PubMed ID: 19222850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of type IIA secretory phospholipase A2 inhibits cholesteryl ester transfer protein activity in transgenic mice.
    Hurt-Camejo E; Gautier T; Rosengren B; Dikkers A; Behrendt M; Grass DS; Rader DJ; Tietge UJ
    Arterioscler Thromb Vasc Biol; 2013 Dec; 33(12):2707-14. PubMed ID: 24115030
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Varespladib (A-002), a secretory phospholipase A2 inhibitor, reduces atherosclerosis and aneurysm formation in ApoE-/- mice.
    Fraser H; Hislop C; Christie RM; Rick HL; Reidy CA; Chouinard ML; Eacho PI; Gould KE; Trias J
    J Cardiovasc Pharmacol; 2009 Jan; 53(1):60-5. PubMed ID: 19129734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Danlou Tablet Fought against Inflammatory Reaction in Atherosclerosis Rats with Intermingled Phlegm and Blood Stasis Syndrome and Its Mechanism Study].
    Chen J; Cai HW; Miao J; Xu XM; Mao W
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2016 Jun; 36(6):703-8. PubMed ID: 27491230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease.
    Rosenson RS; Elliott M; Stasiv Y; Hislop C;
    Eur Heart J; 2011 Apr; 32(8):999-1005. PubMed ID: 21081550
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phospholipase A2 enzymes and the risk of atherosclerosis.
    Rosenson RS; Hurt-Camejo E
    Eur Heart J; 2012 Dec; 33(23):2899-909. PubMed ID: 22802388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial.
    Nicholls SJ; Kastelein JJ; Schwartz GG; Bash D; Rosenson RS; Cavender MA; Brennan DM; Koenig W; Jukema JW; Nambi V; Wright RS; Menon V; Lincoff AM; Nissen SE;
    JAMA; 2014 Jan; 311(3):252-62. PubMed ID: 24247616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The synergistic inhibition of atherogenesis in apoE-/- mice between pravastatin and the sPLA2 inhibitor varespladib (A-002).
    Shaposhnik Z; Wang X; Trias J; Fraser H; Lusis AJ
    J Lipid Res; 2009 Apr; 50(4):623-9. PubMed ID: 19029066
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phospholipase A2 inhibition and atherosclerotic vascular disease: prospects for targeting secretory and lipoprotein-associated phospholipase A2 enzymes.
    Rosenson RS
    Curr Opin Lipidol; 2010 Dec; 21(6):473-80. PubMed ID: 20739882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GM-CSF deficiency reduces macrophage PPAR-gamma expression and aggravates atherosclerosis in ApoE-deficient mice.
    Ditiatkovski M; Toh BH; Bobik A
    Arterioscler Thromb Vasc Biol; 2006 Oct; 26(10):2337-44. PubMed ID: 16873730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids.
    Leitinger N; Watson AD; Hama SY; Ivandic B; Qiao JH; Huber J; Faull KF; Grass DS; Navab M; Fogelman AM; de Beer FC; Lusis AJ; Berliner JA
    Arterioscler Thromb Vasc Biol; 1999 May; 19(5):1291-8. PubMed ID: 10323782
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low-carbohydrate diets reduce lipid accumulation and arterial inflammation in guinea pigs fed a high-cholesterol diet.
    Leite JO; DeOgburn R; Ratliff J; Su R; Smyth JA; Volek JS; McGrane MM; Dardik A; Fernandez ML
    Atherosclerosis; 2010 Apr; 209(2):442-8. PubMed ID: 19892353
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simvastatin inhibits sPLA2 IIa expression in aorta and myocardium.
    Wei-hua L; Chang-qing S; Qiang X; Rong W; Kai-min L
    Arch Med Res; 2009 Feb; 40(2):67-72. PubMed ID: 19237014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Granulocyte-macrophage colony-stimulating factor prevents the progression of atherosclerosis via changes in the cellular and extracellular composition of atherosclerotic lesions in watanabe heritable hyperlipidemic rabbits.
    Shindo J; Ishibashi T; Yokoyama K; Nakazato K; Ohwada T; Shiomi M; Maruyama Y
    Circulation; 1999 Apr; 99(16):2150-6. PubMed ID: 10217656
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Darapladib, a Lipoprotein-Associated Phospholipase A2 Inhibitor, Reduces Rho Kinase Activity in Atherosclerosis.
    Zhang J; Xu DL; Liu XB; Bi SJ; Zhao T; Sui SJ; Ji XP; Lu QH
    Yonsei Med J; 2016 Mar; 57(2):321-7. PubMed ID: 26847282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Role for Matrix Metalloproteinase 9 in Modulation of Cholesterol Metabolism.
    Hernandez-Anzaldo S; Brglez V; Hemmeryckx B; Leung D; Filep JG; Vance JE; Vance DE; Kassiri Z; Lijnen RH; Lambeau G; Fernandez-Patron C
    J Am Heart Assoc; 2016 Sep; 5(10):. PubMed ID: 27694328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analyses of group III secreted phospholipase A2 transgenic mice reveal potential participation of this enzyme in plasma lipoprotein modification, macrophage foam cell formation, and atherosclerosis.
    Sato H; Kato R; Isogai Y; Saka G; Ohtsuki M; Taketomi Y; Yamamoto K; Tsutsumi K; Yamada J; Masuda S; Ishikawa Y; Ishii T; Kobayashi T; Ikeda K; Taguchi R; Hatakeyama S; Hara S; Kudo I; Itabe H; Murakami M
    J Biol Chem; 2008 Nov; 283(48):33483-97. PubMed ID: 18801741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Group v secretory phospholipase A2 promotes atherosclerosis: evidence from genetically altered mice.
    Bostrom MA; Boyanovsky BB; Jordan CT; Wadsworth MP; Taatjes DJ; de Beer FC; Webb NR
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):600-6. PubMed ID: 17204667
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Appropriate doses of granulocyte-colony stimulating factor reduced atherosclerotic plaque formation and increased plaque stability in cholesterol-fed rabbits.
    Matsumoto T; Watanabe H; Ueno T; Tsunemi A; Hatano B; Kusumi Y; Mitsumata M; Fukuda N; Matsumoto K; Saito S; Mugishima H
    J Atheroscler Thromb; 2010 Feb; 17(1):84-96. PubMed ID: 20081322
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overexpression of Toll-Like Receptors 2, 3, 4, and 8 Is Correlated to the Vascular Atherosclerotic Process in the Hyperlipidemic Rabbit Model: The Effect of Statin Treatment.
    Kapelouzou A; Giaglis S; Peroulis M; Katsimpoulas M; Moustardas P; Aravanis CV; Kostakis A; Karayannakos PE; Cokkinos DV
    J Vasc Res; 2017; 54(3):156-169. PubMed ID: 28478461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.